论文部分内容阅读
目的评价基因重组生长激素(rHGH)在慢性阻塞性肺疾病(COPD)患者双相气道正压通气(BiPAP)治疗过程中的临床疗效。方法选择30例在呼吸内科住院的COPD呼吸衰竭需BiPAP无创通气的病人,随机分为rHGH组和对照组各15例,rHGH组除常规治疗外另予以rHGH8 IU/d。观察两组BiPAP通气时间、治疗期间两组病人的血浆蛋白值、细胞免疫功能及血糖的变化。结果rHGH组需BiPAP通气持续时间短于对照组,治疗后CD4、NKC活性、血浆白蛋血、转铁蛋白、前铁蛋白的浓度升高(P<0.05)。两组治疗前后的血糖值差异无统计学意义。结论rHGH可以改善COPD患者的细胞免疫功能,促进蛋白质合成,缩短BiPAP通气治疗时间。
Objective To evaluate the clinical efficacy of recombinant human growth hormone (rHGH) in the treatment of bipolar positive airway pressure (BiPAP) in patients with chronic obstructive pulmonary disease (COPD). Methods Thirty patients with COPD respiratory failure requiring BiPAP hospitalized in respiratory medicine were randomly divided into rHGH group (n = 15) and control group (n = 15). Patients in rHGH group were treated with rHGH8 IU / d. The duration of BiPAP ventilation, the plasma protein value, cellular immune function and blood glucose of two groups were observed during the treatment. Results The duration of BiPAP ventilation in rHGH group was shorter than that in control group. After treatment, CD4, NKC activity, plasma albumin, transferrin and pretoferrin increased (P <0.05). There was no significant difference in blood glucose between the two groups before and after treatment. Conclusion rHGH can improve cellular immune function, promote protein synthesis and shorten the time of BiPAP ventilation in COPD patients.